4 results about "Cns inflammation" patented technology

The invention relates to application of NADH (nicotinamide adenine dinucleotide) in preparation of drugs for preventing or treating autism, and further provides a liposome nanoparticle oral preparation for preventing or treating autism, the NADH can reduce central nervous system inflammation, and tests prove that the NADH can remarkably reduce neural immune inflammation of autism model rats, and can be used for preventing or treating autism. The method has the advantages that the method is simple and convenient to operate and has neuroprotection and progeny rat behavioral correction capacity, social experiment defects of progeny rats are overcome, the engraving behaviors of the progeny rats are reduced, the influence of autism-related behaviors of the progeny rats is reversed, and a new scheme is provided for prevention or treatment of autism.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

This invention discloses a compound with a pyrrolopyridine structure, its preparation method, and its pharmaceutical uses. This invention provides a novel compound with a pyrrolopyridine structure and a method for synthesizing this series of compounds. Activity studies show that the compound with the pyrrolopyridine structure possesses excellent JAK protein kinase inhibitory activity. Those skilled in the art know that JAK protein kinase plays an important role in the occurrence and development of various diseases, such as various immune diseases, myeloproliferative disorders, and central nervous system inflammatory diseases; inhibiting JAK can treat or alleviate these diseases. Therefore, the compound with the pyrrolopyridine structure provided by this invention has the potential for development into a JAK inhibitor drug and for treating or alleviating diseases by inhibiting JAK.

Providing compositions and methods for targeting inflammatory cells or activated cells to treat or improve inflammatory conditions and pain. [Solution] A method is provided for modifying the amino acid sequence and increasing the expression level of ApoA-I binding protein for treating neuropathic pain, CNS inflammation, allodynia, post-neuropathy pain, postoperative pain, chemotherapy-induced peripheral neuropathy, neurodegenerative diseases or conditions such as Alzheimer's disease, hyperalgesia, primary headaches such as migraines and cluster headaches, glaucoma or other inflammatory eye diseases, pneumonia, asthma, HIV infection, vasculitis, atherosclerosis and cardiovascular diseases.